US Stock Market Move | Biopharmaceutical company Evommune (EVMN.US) debuts on the US stock market with a stock price surge of over 15%.
As of the time of publication, the stock has risen by over 15%, to $18.38.
Evommune (EVMN.US) listed on the US stock market, with the stock rising over 15% to $18.38 as of the time of writing, compared to its IPO price of $16. Evommune is a clinical-stage biopharmaceutical company with a mission to treat "immune-mediated chronic inflammatory diseases" through innovative therapies. These diseases include chronic urticaria, atopic dermatitis, and other conditions related to mast cells/inflammation.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
